Ok, I have dropped the ball on this..the trial started in Feb 2024 and I have missed it, it was not on my list! But here it is…
A new Phase I clinical trial will assess an investigational small-molecule inhibitor (VVD-130850) that targets the STAT3 transcription factor in advanced solid and hematologic tumors. The drug binds a novel allosteric pocket on STAT3, inhibiting DNA binding and gene expression without changing STAT3’s overall level. STAT3 is known to promote tumor growth, metastasis, and immune evasion in many cancers, including prostate cancer.
The agent was discovered through a chemoproteomics platform that identifies underexplored protein pockets and develops highly selective compounds. This trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and initial anti-tumor effects.
